Related Experiment Video
Updated: Jul 19, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Gastrodin destabilizes survivin and overcomes pemetrexed resistance
Jinzhuang Liao1, Xiang Qing2, Gaoyan Deng3
1Department of Radiology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China; Cell Transplantation and Gene Therapy Institute, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Abstract:
Survivin is a bifunctional protein that plays crucial roles in tumorigenesis. In the present study, we discovered that the natural product gastrodin suppressed the cell viability and colony formation of non-small cell lung cancer (NSCLC) cell lines A549, HCC827, and H460 in a dose-dependent manner. In addition, gastrodin enhanced the protein levels of cleaved-caspase 3 by activating the endogenous mitochondrial apoptosis pathway. Gastrodin inhibits protein kinase B (Akt)/WEE1/cyclin-dependent kinase 1 (CDK1) signaling to downregulate survivin Thr34 phosphorylation. Survivin Thr34 dephosphorylation caused by gastrodin interfered with the binding of ubiquitin-specific protease 19 (USP19), which eventually destabilized survivin. We revealed that the growth of NSCLC xenograft tumors was markedly suppressed by gastrodin in vivo. Furthermore, gastrodin overcomes pemetrexed resistance in vivo or in vitro. Our results suggest that gastrodin is a potential antitumor agent by reducing survivin in NSCLC.
Insights
Gastrodin, a natural compound, effectively inhibits non-small cell lung cancer (NSCLC) growth by reducing survivin levels. It also enhances apoptosis and overcomes resistance to chemotherapy, showing potential as an antitumor agent.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Survivin is a key protein in cancer development.
- Non-small cell lung cancer (NSCLC) remains a significant health challenge.
- Targeting survivin offers a potential therapeutic strategy for NSCLC.
Purpose of the Study:
- To investigate the antitumor effects of gastrodin on NSCLC.
- To elucidate the molecular mechanisms underlying gastrodin's action.
- To evaluate gastrodin's potential in overcoming chemotherapy resistance.
Main Methods:
- Cell viability and colony formation assays in NSCLC cell lines.
- Western blotting to assess protein levels and signaling pathways.
- In vivo xenograft tumor models and in vitro drug resistance studies.
Main Results:
- Gastrodin suppressed NSCLC cell viability and colony formation dose-dependently.
- Gastrodin induced apoptosis by activating the mitochondrial pathway and enhancing cleaved-caspase 3.
- Gastrodin inhibited Akt/WEE1/CDK1 signaling, leading to survivin dephosphorylation and destabilization.
- Gastrodin reduced NSCLC tumor growth in vivo and overcame pemetrexed resistance.
Conclusions:
- Gastrodin exhibits significant antitumor activity against NSCLC.
- Gastrodin's mechanism involves survivin downregulation via dephosphorylation and destabilization.
- Gastrodin demonstrates potential as a therapeutic agent for NSCLC, including overcoming drug resistance.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Drugs that Destabilize Microtubules
Abnormal Proliferation
Drugs that Stabilize Microtubules
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

